HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Class 3 semaphorins as a therapeutic target.

AbstractINTRODUCTION:
The semaphorins were initially described as axon guidance molecules that play important roles in the development of nervous system. Recent studies suggest that semaphorins and their receptors also exert such diverse functions as immune response, control of vascular endothelial cell motility and invasion of many types of cancer cells.
AREAS COVERED:
The available results concerning application of class 3 semaphorins and their inhibitors for the treatment in animal disease models.
EXPERT OPINION:
Because semaphorins are now recognized as key players in immune, cardiovascular, bone metabolism and neurological system, semaphorins and their receptors are most promising therapeutic targets for various disease states. As semaphorins exert their diverse or even opposing activities in vivo, more elaborate studies on pathophysiology and signal transduction mechanisms of semaphorins are required.
AuthorsYoshio Goshima, Yukio Sasaki, Naoya Yamashita, Fumio Nakamura
JournalExpert opinion on therapeutic targets (Expert Opin Ther Targets) Vol. 16 Issue 9 Pg. 933-44 (Sep 2012) ISSN: 1744-7631 [Electronic] England
PMID22834859 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Semaphorins
Topics
  • Animals
  • Gene Expression Regulation (drug effects, physiology)
  • Humans
  • Models, Molecular
  • Protein Conformation
  • Semaphorins (chemistry, genetics, metabolism)
  • Signal Transduction (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: